EP0655924A4 - COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION. - Google Patents

COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.

Info

Publication number
EP0655924A4
EP0655924A4 EP93906955A EP93906955A EP0655924A4 EP 0655924 A4 EP0655924 A4 EP 0655924A4 EP 93906955 A EP93906955 A EP 93906955A EP 93906955 A EP93906955 A EP 93906955A EP 0655924 A4 EP0655924 A4 EP 0655924A4
Authority
EP
European Patent Office
Prior art keywords
erbb
combination
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93906955A
Other languages
German (de)
English (en)
Other versions
EP0655924A1 (fr
Inventor
Philip G Kasprzyk
Charles R King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncologix Inc
Original Assignee
Oncologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologix Inc filed Critical Oncologix Inc
Publication of EP0655924A1 publication Critical patent/EP0655924A1/fr
Publication of EP0655924A4 publication Critical patent/EP0655924A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93906955A 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION. Withdrawn EP0655924A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90655592A 1992-06-30 1992-06-30
US906555 1992-06-30
PCT/US1992/008545 WO1994000136A1 (fr) 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION

Publications (2)

Publication Number Publication Date
EP0655924A1 EP0655924A1 (fr) 1995-06-07
EP0655924A4 true EP0655924A4 (fr) 1996-09-11

Family

ID=25422648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93906955A Withdrawn EP0655924A4 (fr) 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.

Country Status (6)

Country Link
EP (1) EP0655924A4 (fr)
JP (1) JPH08504172A (fr)
KR (1) KR100269879B1 (fr)
AU (1) AU687346B2 (fr)
CA (1) CA2120745A1 (fr)
WO (1) WO1994000136A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (fr) 1997-12-12 2012-12-19 Genentech, Inc. Traitement du cancer avec un anticorps Anti-ERBB2 combiné à une chimiothérapie
EP1941905A1 (fr) 1998-03-27 2008-07-09 Genentech, Inc. Synergie d'anticorps APO-2 ligand-anti-her-2
EP2264166B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
BRPI0017590B8 (pt) 1999-06-25 2021-05-25 Genentech Inc conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
EP2266607A3 (fr) 1999-10-01 2011-04-20 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001076630A1 (fr) * 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et remedes contre la polyarthrite rhumatoide
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
CN104383535A (zh) 2000-05-19 2015-03-04 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2481515C (fr) 2002-04-10 2013-10-01 Genentech, Inc. Variants d'anticorps anti-her2
PT1585966E (pt) 2002-07-15 2012-02-20 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
KR101088661B1 (ko) * 2002-10-10 2011-12-01 메르크 파텐트 게엠베하 Ｅｒｂ－ｂ１ 수용체를 표적으로 하는 약학적 조성물
CN100408097C (zh) * 2002-10-10 2008-08-06 默克专利有限公司 双特异性抗erb-b抗体及其在肿瘤治疗中的用途
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2592177A1 (fr) 2005-01-21 2006-07-27 Genentech, Inc. Dosage fixe d'anticorps anti-her
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
MX2009008909A (es) 2007-03-01 2009-08-28 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
CA2917355C (fr) 2007-06-08 2018-07-17 Genentech, Inc. Marqueurs d'expression de gene de resistance tumorale a un traitement r inhibiteur her2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
HUE061746T2 (hu) 2007-07-09 2023-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010022736A2 (fr) 2008-08-29 2010-03-04 Symphogen A/S Compositions de l'anticorps de recombinaison anti-récepteur du facteur de croissance anti-épidermique egfr
WO2010108127A1 (fr) 2009-03-20 2010-09-23 Genentech, Inc. Anticorps anti-her di-spécifiques
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011130580A1 (fr) 2010-04-15 2011-10-20 Alper Biotech, Llc Anticorps monoclonaux contre antigènes her2 et leurs utilisations
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012084829A1 (fr) 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Préparation d'anticorps enrichie en isoformes et son procédé d'obtention
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
WO2013033380A1 (fr) 2011-08-31 2013-03-07 Genentech, Inc. Marqueurs de diagnostic
WO2013063229A1 (fr) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Traitement par un agent de ciblage de her2 dans des cancers non amplifiés par her2 ayant des cellules souches cancéreuses exprimant her2
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2914633B1 (fr) 2012-10-30 2021-12-08 Esperance Pharmaceuticals, Inc. Conjugués anticorps/médicament et leurs procédés d'utilisation
CA2889298C (fr) 2012-11-30 2024-01-02 Anton Belousov Identification de patients ayant besoin d'une cotherapie par un inhibiteur de pd-l1
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
RU2689145C2 (ru) 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
CN107787331B (zh) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 抗her2抗体和使用方法
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
EP3712178A4 (fr) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation Anticorps anti-her2 ou fragment de liaison à l'antigène de celui-ci, et récepteur antigénique chimérique le comprenant
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
IL268443B2 (en) 2018-04-17 2024-07-01 Molecular Templates Inc HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
US12209131B2 (en) 2018-08-16 2025-01-28 Cantargia Ab Anti-IL1RAP antibody compositions
EP4405396A2 (fr) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer positif her2
GB202309703D0 (en) 2023-06-27 2023-08-09 Epsilogen Ltd Composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (fr) * 1988-02-26 1989-09-06 Neorx Corporation Anticorps fonctionnellement spécifiques
WO1991005264A1 (fr) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (fr) * 1988-02-26 1989-09-06 Neorx Corporation Anticorps fonctionnellement spécifiques
WO1991005264A1 (fr) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KASPRZYK ET AL: "THERAPY OF AN ANIMAL MODEL OF HUMAN GASTRIC CANCER USING A COMBINATION OF ANTI-ERBB-2 MONOCLONAL ANTIBODIES", CANCER RESEARCH, vol. 52, 15 May 1992 (1992-05-15), pages 2771 - 2776, XP002014292 *
See also references of WO9400136A1 *

Also Published As

Publication number Publication date
WO1994000136A1 (fr) 1994-01-06
KR950700075A (ko) 1995-01-16
CA2120745A1 (fr) 1994-01-06
JPH08504172A (ja) 1996-05-07
KR100269879B1 (ko) 2000-10-16
EP0655924A1 (fr) 1995-06-07
AU687346B2 (en) 1998-02-26
AU3773393A (en) 1994-01-24

Similar Documents

Publication Publication Date Title
EP0655924A4 (fr) COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.
HU9601574D0 (en) Humanized antibodies and uses thereof
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
AU4289496A (en) Method of promoting an immune response with a bispecific antibody
AU4618193A (en) Humanized antibodies
AU6080794A (en) Antibodies directed against binding-associated epitopes
NZ230786A (en) A method of reducing the heterogeneity of secreted monoclonal antibodies
EP0578515A3 (fr) Anticorps monoclonaux humanisés.
GB9608626D0 (en) Hepatitis b monoclonal antibodies
GB9412166D0 (en) Retargetting antibodies
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
EP0506523A3 (en) Monoclonal antibodies
EP0909278A4 (fr) Immunoglobuline g liee a la nephropathie et anticorps contre celle-ci
EP0218587A4 (fr) Anticorps monoclonaux et procede d'immunisation les utilisant.
ZA89258B (en) Monoclonal antibodies
EP0582450A3 (fr) Anticorps contre récepteur de l'oxytocine et leur production.
EP0654532A4 (fr) Anticorps monoclonal antimucoglycoproteine.
GB8820036D0 (en) Monoclonal antibodies
EP0468056A4 (en) Anti-procollagenase monoclonal antibodies and a method for the assay of procollagenase utilizing thereof
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
GB9212074D0 (en) Monoclonal antibody
SG64332A1 (en) Monoclonal antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 35/14

RHK1 Main classification (correction)

Ipc: C12N 15/13

A4 Supplementary search report drawn up and despatched

Effective date: 19960726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 20000712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010123